ASX Announcement

Recce Pharmaceuticals
recce.com.au
ACN 124 849 065

Abstract & Poster Presentation at Military Health System Research Symposium 2023

SYDNEY Australia, 27 July 2023: Recce Pharmaceuticals Ltd (**ASX:RCE**, **FSE:R9Q**) (the **Company**), the Company developing a new class of Synthetic Anti-infectives, has received confirmation a research Abstract and Poster presentation will be published at the 2023 Military Health System Research Symposium (MHSRS).

The Abstract & Poster publications will be accompanied by an in-person, oral presentation by Dr John Prendergast, Executive Chairman of Recce Pharmaceuticals. The speaking session focuses on antimicrobial countermeasures for wound infections in military personnel. The abstract presents expanded details of *in-vitro, in-vivo* and human clinical trial data supporting the Company's lead synthetic anti-infective RECCE® 327.

Session

Antimicrobial Countermeasures for Wound Infections in Military Personnel

Title

RECCE® 327: A Novel Synthetic Anti-infective for the Treatment of Antimicrobial-resistant Bacterial Sepsis Infections

The MHSRS is the United States (US) Department of Defence's foremost scientific meeting. It provides a venue for presenting new scientific knowledge particular to military specific focuses in research and development. The MHSRS is the premier US military and select civilian meeting that draws approximately 3,500 attendees with focus to the unique medical needs of the Warfighter. The symposium will be held in Kissimmee, Florida 14-17 August 2023.

A non-confidential version of the Poster and Abstract materials will be available on the Company's website, post-conference.

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: **RCE**, FSE: **R9Q**) is developing a new class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world's only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.

recce.com.au
ACN 124 849 065

Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Media and Investor Relations

Australia
Andrew Geddes
CityPR
+61 408 677 734
ageddes@citypublicrelations.com.au

USA
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com